Literature DB >> 15181000

The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution.

Michael R Wester1, Jason K Yano, Guillaume A Schoch, Christine Yang, Keith J Griffin, C David Stout, Eric F Johnson.   

Abstract

The structure of human P450 2C9 complexed with flurbiprofen was determined to 2.0 A by x-ray crystallography. In contrast to other structurally characterized P450 2C enzymes, 2C5, 2C8, and a 2C9 chimera, the native catalytic domain of P450 2C9 differs significantly in the conformation of the helix F to helix G region and exhibits an extra turn at the N terminus of helix A. In addition, a distinct conformation of the helix B to helix C region allows Arg-108 to hydrogen bond with Asp-293 and Asn-289 on helix I and to interact directly with the carboxylate of flurbiprofen. These interactions position the substrate for regioselective oxidation in a relatively large active site cavity and are likely to account for the high catalytic efficiency exhibited by P450 2C9 for the regioselective oxidation of several anionic non-steroidal anti-inflammatory drugs. The structure provides a basis for interpretation of a number of observations regarding the substrate selectivity of P450 2C9 and the observed effects of mutations on catalysis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15181000     DOI: 10.1074/jbc.M405427200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  105 in total

1.  Exploration of the binding of curcumin analogues to human P450 2C9 based on docking and molecular dynamics simulation.

Authors:  Rongwei Shi; Yin Wang; Xiaolei Zhu; Xiaohua Lu
Journal:  J Mol Model       Date:  2011-11-12       Impact factor: 1.810

Review 2.  Conformational plasticity and structure/function relationships in cytochromes P450.

Authors:  Thomas C Pochapsky; Sophia Kazanis; Marina Dang
Journal:  Antioxid Redox Signal       Date:  2010-10       Impact factor: 8.401

3.  Improved ligand-protein binding affinity predictions using multiple binding modes.

Authors:  Eva Stjernschantz; Chris Oostenbrink
Journal:  Biophys J       Date:  2010-06-02       Impact factor: 4.033

4.  Electrocatalytic drug metabolism by CYP2C9 bonded to a self-assembled monolayer-modified electrode.

Authors:  Mingli Yang; Jarod L Kabulski; Lance Wollenberg; Xinqi Chen; Murali Subramanian; Timothy S Tracy; David Lederman; Peter M Gannett; Nianqiang Wu
Journal:  Drug Metab Dispos       Date:  2009-01-26       Impact factor: 3.922

5.  Carbon-carbon bond cleavage in activation of the prodrug nabumetone.

Authors:  Fatbardha Varfaj; Siti N A Zulkifli; Hyoung-Goo Park; Victoria L Challinor; James J De Voss; Paul R Ortiz de Montellano
Journal:  Drug Metab Dispos       Date:  2014-02-28       Impact factor: 3.922

6.  Characterization of inhibition kinetics of (S)-warfarin hydroxylation by noscapine: implications in warfarin therapy.

Authors:  Nan Zhang; Ryan P Seguin; Kent L Kunze; Yan-Yan Zhang; Hyunyoung Jeong
Journal:  Drug Metab Dispos       Date:  2013-09-17       Impact factor: 3.922

Review 7.  Cholesterol-metabolizing cytochromes P450: implications for cholesterol lowering.

Authors:  Irina A Pikuleva
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-11       Impact factor: 4.481

8.  Selective, competitive and mechanism-based inhibitors of human cytochrome P450 2J2.

Authors:  Pierre Lafite; Sylvie Dijols; Darryl C Zeldin; Patrick M Dansette; Daniel Mansuy
Journal:  Arch Biochem Biophys       Date:  2007-04-10       Impact factor: 4.013

9.  The role of Ile476 in the structural stability and substrate binding of human cytochrome P450 2C8.

Authors:  Lu Sun; Zhong-Hua Wang; Feng-Yun Ni; Xiang-Shi Tan; Zhong-Xian Huang
Journal:  Protein J       Date:  2010-01       Impact factor: 2.371

10.  Characterization of CYP2A13*2, a variant cytochrome P450 allele previously found to be associated with decreased incidences of lung adenocarcinoma in smokers.

Authors:  Jaime D'Agostino; Xiuling Zhang; Hong Wu; Guoyu Ling; Suping Wang; Qing-Yu Zhang; Fucai Liu; Xinxin Ding
Journal:  Drug Metab Dispos       Date:  2008-07-31       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.